Helus Pharma Inc.
HELPAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wells Fargo | maintain | Overweight | Oct 22, 2026 |
| TD Cowen | maintain | Buy | Aug 20, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 9, 2026 |
| Canaccord Genuity | maintain | Buy | Jul 1, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 2, 2026 |
| Guggenheim | maintain | Buy | Dec 3, 2025 |
| Canaccord Genuity | maintain | Buy | Nov 20, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 14, 2025 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.67| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.91 | $-0.80 | — | — |
| Jun 30, 2026 | $-0.96 | $-1.04 | — | — |
| Feb 13, 2026 | $-0.99 | $-0.53 | — | — |
| Nov 13, 2025 | $-1.39 | $-0.74 | — | — |
| Aug 13, 2025 | $-1.10 | $-0.96 | — | — |
| Jul 1, 2025 | $-1.01 | $-0.85 | — | — |
| Feb 11, 2025 | $-0.37 | $-0.73 | — | — |
| Nov 13, 2024 | $-2.86 | $-0.98 | — | — |
News
Shares of Cybin Inc. (NASDAQ: HELP - Get Free Report) have been assigned an average rating of "Buy" from the six analysts that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued ratings on the stock in
CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT
Co-founders to step down from executive roles and continue to serve on the Board of Directors Helus Pharma board member, Mark Lawson, appointed as new independent Chair of the Board of Directors, effective immediately This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Oct. 27, 2026 (GLOBE NE…
Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder (“MDD”) on track for Q4 20261,2
This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.
Helus Pharma remains a buy, as HLP003's Phase 3 APPROACH topline data in 4Q26 is the key near-term catalyst. HLP003 targets adjunctive MDD with a differentiated intermittent dosing model; prior Phase 2 data showed a 23-point MADRS reduction and 71% remission at 12 months. HELP's $166.4M cash balance provides 12–14 months runway, but dilution risk persists given high operating outflows and the $100M ATM facility.
NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce that the Company will host an investor presentation on October 21, 2026.
NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company's legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at the Company's annual and special meeting of shareholders held on Se…
Helus Pharma, formerly known as Cybin NASDAQ: HELP, outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen's Novel Mechanisms in Neuropsychiatry virtual summit.
Cybin (NASDAQ: HELP), doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company's auditor, board size, corporate name and director elections. Eric So, the company's co-founder and executive chairman, chaired the virtual meeting, which was hosted through Odyssey Trust Company's shareholder
TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”). There were 107 shareholders represented in person or by proxy at the Meeting hol…
Cybin NASDAQ: HELP, doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company's auditor, board size, corporate name and director elections.
CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT
Poster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment for major depressive disorder (“MDD”) NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the presentation of four posters …
Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company's mental health treatment pipeline. Speaking at the Morgan Stanley 24th Annual Global Healthcare Conference, Halstead,
Cybin NASDAQ: HELP executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright's 28th Annual Global Investment Conference.
Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company's mental health treatment pipeline.
Cybin Inc. (NASDAQ: HELP - Get Free Report) insider Eric So acquired 100,000 shares of the stock in a transaction on Tuesday, September 8th. The shares were acquired at an average price of $12.39 per share, for a total transaction of $1,239,000.00. Following the acquisition, the insider owned 4,465,014 shares of the company's stock, valued at
CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. EDT. CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. EDT.
CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT